EUVIMEDEUVIMED entdecken
Crossref

Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models

Cheng Long, Hui Shen, Hui Li iD, Lan Han

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.13042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Cheng Long und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Cisplatin, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Xiangyang Medical and Health Instructional Science and Technology Action Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer for which platinum‐based chemotherapy is the standard of care. Despite an initial response to this therapy, patients eventually develop resistance to the chemotherapy.

Objectives

To investigate the potential of capivasertib, an approved drug for advanced breast cancer, to enhance the efficacy of cisplatin in preclinical SCLC models and explore the underlying mechanisms.

Methods

SCLC cell lines were treated with capivasertib and cisplatin, alone or in combination, to assess cell viability, proliferation, colony formation, and apoptosis. Next, capivasertib's effects, alone and combined with cisplatin, were evaluated in an SCLC mouse model. Mechanistic studies focused on Akt and MYC signaling, with constitutively active Akt overexpression used to assess its role.

Results

Capivasertib is active against a panel of SCLC cell lines regardless of cellular origin and genetic profiling with IC50 at a clinically achievable range. Particularly, capivasertib inhibits proliferation and anchorage‐independent colony formation and induces apoptosis in SCLC cells. It significantly augments cisplatin's inhibitory effects in all tested cell lines. Importantly, capivasertib at a non‐toxic dose is effective in delaying SCLC growth in mice and its combination with cisplatin achieves nearly complete tumor growth inhibition. Mechanistic studies confirm that capivasertib inhibits Akt and MYC signaling, and furthermore, that overexpression of constitutively active Akt reversed anti‐SCLC activity of capivasertib.

Conclusion

Our work is the first to reveal that Akt inhibition can augment chemotherapy in SCLC, and capivasertib is a useful addition to the treatment armamentarium for SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsCisplatinProto-Oncogene Proteins c-aktApoptosisPyrimidinesCell ProliferationDrug SynergismXenograft Model Antitumor AssaysAnimalsHumansCell Line, TumorMiceAntineoplastic Combined Chemotherapy ProtocolsPyrrolesCell SurvivalFemaleAntineoplastic AgentsMice, NudeSignal Transduction

Stichwörter der Autor:innen

AktMYCSCLCcapivasertibchemoresistance

Substanzen

CisplatinProto-Oncogene Proteins c-aktPyrimidinescapivasertibPyrrolesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei Province, China.

ORCID-Profile: Hui Li

Förderung

  • Xiangyang Medical and Health Instructional Science and Technology Action Plan Project

Zitieren

APA

Long, C., Shen, H., Li, H., & Han, L. (2025). Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13042

Vancouver

Long C, Shen H, Li H, Han L. Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.13042

BibTeX
@article{Long2025,
  author = {Long, Cheng and Shen, Hui and Li, Hui and Han, Lan},
  title = {Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.13042}
}
Kostenlos starten →